See package insert. How to take and store Felbamate? Follow your doctor’s directions. Call if you have any questions. Usually, your doctor will tell you to start by. Felbatol is the brand name used in the United States for felbamate. Read the black box warning in the Package Insert to your patient and obtain any necessary . Felbamate, also known as Felbatol, has been approved by the Food and Drug about all potential risks before using this drug and read the package insert.
||11 September 2011
|PDF File Size:
|ePub File Size:
||Free* [*Free Regsitration Required]
Patients must call to enroll in the registry. Felbamate may cause hepatotoxicity and hepatic failure. Monitoring of the anticonvulsant serum concentration is recommended. Coadministration may increase cannabidiol plasma concentrations increasing the risk of adverse reactions. The serious toxicities of felbamate, such as aplastic anemia, would also warrant that felbamate be used during pregnancy only if clearly needed. Dosage adjustment of methsuximide may be required. If these drugs are used together, monitor for escitalopram-associated adverse reactions.
Clinical manifestations may not be present for several months after therapy is initiated; where data are available the onset has ranged from 5 to 30 weeks after the start of therapy.
Therapeutic drug monitoring pacmage not required or available for most anticonvulsants. Valproic Acid, Divalproex Sodium: The exact mechanism by which felbamate exerts its anticonvulsant activity is unknown. Amphetamines may decrease the seizure threshold and may increase the risk of seizures. Major Estrogens and progestins are both susceptible to drug interactions with hepatic enzyme inducing drugs. Previously untreated patients should be titrated under close clinical supervision.
In rats, there was a decrease in pup weight and an increase in pup deaths felbamatf lactation; the reason for the deaths is not determined. If felbamate must be used, consider reducing use of other CNS-active medications that increase the risk of falls and fractures and implement other strategies to reduce fall risk. Major Coadministration of felbamate and clarithromycin may decrease clarithromycin serum concentrations due to CYP3A4 enzyme induction.
Major Avoid concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis, such as felbamate; however, if this is not possible, closely monitor the absolute neutrophil count and interrupt deferiprone therapy if neutropenia develops. Higher lidocaine doses may be required; titrate to effect.
Felbatol (felbamate) dose, indications, adverse effects, interactions from
Monitoring should include baseline liver function tests i. The relative risk for suicidality was pacage in patients with epilepsy compared to those with other conditions; however, the absolute risk differences were similar in trials for epilepsy and psychiatric indications.
However, this is considered to be a class effect. For storage information, see specific product information within the How Supplied section. Oral anticonvulsant agent chemically similar to meprobamate, but does not possess muscle-relaxant activity. Felbamate should be discontinued if signs and symptoms of hematologic abnormalities or any sign of bone marrow depression occurs.
Monitor for a decrease in maraviroc efficacy with concomitant imsert. Oral dosage-Conversion to Monotherapy. Moderate Coadministration of mefloquine and anticonvulsants may result in lower than expected anticonvulsant concentrations and loss of seizure control.
Your Name Your name is required. Major Coadministration of felbamate with atazanavir is not recommended. The need for indefinite continuation in treating any condition should be based on confirmation of the condition and its potential cause s. Felbamate is a potent inhibitor of CYP2C Use clopidogrel and felbamate together with caution and monitor for reduced efficacy of clopidogrel. Felbamate has not been systematically studied as initial monotherapy. The manufacturer advises lnsert avoid use of felbamate in patients with pre-existing hepatic disease.
Coadministration may decrease felamate plasma concentrations of ivabradine resulting in the potential for treatment failure. Moderate Amoxapine, when used concomitantly with anticonvulsants, can increase CNS depression and may also lower the seizure threshold, leading to pharmacodynamic interactions.
High or toxic serum concentrations should become a consideration for dosage adjustments. Taking these drugs together may decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy.